Valuation
- Market cap
- 366,105,000
- Revenue TTM
- $0
- Net income TTM
- $-62,056,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 176,980
- Avg volume
- —
- Day's range
- $11.84 – $12.80
- Shares out
- 29,079,000
- Stochastic %K
- 32%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both spor...
Show more
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (858) 263-1222
- Website
- https://www.aspenneuroscience.com
- Address
- 10835 Road to the Cure, Suite 100, San Diego, United States
Latest news
No headlines yet.